Gujarat Themis Biosyn Limited
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Gujarat Themis Biosyn Limited's yearly results (2023–2026), compared with Healthcare companies in India. Tap ? on any ratio for what it means.
What stands out
- Growth Efficiency Ratio: Sales grew 12% in 3 years, but profit fell: ₹64 less profit per ₹100 of extra sales. Lower than 98% of Healthcare companies in India.
- Tangible Assets Ratio: Of every ₹100 the company owns, ₹100 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles. More tangible than 92% of Healthcare companies in India.
- Tangible Net Worth Ratio: Of every ₹100 of net worth, ₹100 is tangible; the rest is goodwill and other intangibles, often from buying other companies. More tangible than 90% of Healthcare companies in India.
Where ₹100 of sales goes
Latest year (Mar 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
₹132Over the last 3 years, every ₹100 of reported profit came with ₹132 of operating cash.
Higher than 63% of Healthcare companies in India.
Self-Funding Ratio
0.6×Over the last 3 years its own operating cash paid for 56% of its investment spending (capex); the rest came from other sources such as borrowing, cash reserves or new shares.
Lower than 79% of Healthcare companies in India.
Cash Locked Ratio
₹23For every ₹100 of sales, ₹23 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ₹15 tied up three years earlier.
Less money tied up than 51% of Healthcare companies in India.
Growth quality
Steadiness Ratio
2/3 · 1/3Sales grew in 2 of the last 3 years; profit grew in 1 of 3.
Less steady than 84% of Healthcare companies in India.
Growth Efficiency Ratio
−₹64Sales grew 12% in 3 years, but profit fell: ₹64 less profit per ₹100 of extra sales.
Lower than 98% of Healthcare companies in India.
Asset Productivity Ratio
+12% / +203%In 3 years sales changed by +12% while total assets changed by +203%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
1.5×Debt due within a year is covered 1.5 times by its yearly operating cash.
Higher than 53% of Healthcare companies in India.
Cash Cushion Ratio
−3%Debt, after subtracting cash, equals 3% of its market value (net debt).
Lower than 59% of Healthcare companies in India.
Tangible Assets Ratio
100%Of every ₹100 the company owns, ₹100 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 92% of Healthcare companies in India.
Tangible Net Worth Ratio
100%Of every ₹100 of net worth, ₹100 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 90% of Healthcare companies in India.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Gujarat Themis Biosyn Limited owes ₹0.43 for every ₹1 it owns. Net profit fell 4% in the year to Mar 2026, and shrank 7% a year on average over 3 years.
Compared with Healthcare companies in India · latest annual results Mar 2026.
P/E ratio
79.1Investors pay ₹79.1 for every ₹1 of Gujarat Themis Biosyn Limited's yearly profit, higher than 86% of Healthcare companies in India.
P/B ratio
15.98The share price is 15.98 times Gujarat Themis Biosyn Limited's book value per share, higher than 94% of Healthcare companies in India.
Market cap
₹4,600 CrThe total market value of all of Gujarat Themis Biosyn Limited's shares at today's price (share price × number of shares), smaller than 51% of Healthcare companies in India. PosiCap size class: Mini Cap.
Net worth (book value)
₹288 CrWhat Gujarat Themis Biosyn Limited would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
₹22.11Net worth divided by the number of shares. The share price of ₹353.40 is 16.0 times this, which is the P/B above.
Return on equity (ROE)
16.9%Gujarat Themis Biosyn Limited earned 16.9% on its shareholders' money over the last year, higher than 65% of Healthcare companies in India.
Owes vs Owns
0.43×Gujarat Themis Biosyn Limited owes ₹0.43 for every ₹1 it owns (low), higher than 67% of Healthcare companies in India.
Dividend yield
0.18%Gujarat Themis Biosyn Limited pays 0.18% of its share price as dividends a year, lower than 72% of dividend-paying Healthcare companies in India.
Revenue growth
+10%Revenue rose 10% in the year to Mar 2026, and grew 4% a year on average over 3 years.
Profit growth
-4%Net profit fell 4% in the year to Mar 2026, and shrank 7% a year on average over 3 years.
Profit margin
28.2%Gujarat Themis Biosyn Limited keeps ₹28 of every ₹100 of revenue as net profit.
Cash quality
1.04×Cash from Gujarat Themis Biosyn Limited's business was 1.04× its reported profit in the year to Mar 2026 — its profit turned into cash.
Interest cover
18.6×Gujarat Themis Biosyn Limited's operating profit covered its interest costs 18.6 times in the year to Mar 2026.
Cash vs debt
Net debtGujarat Themis Biosyn Limited had ₹158 Cr more debt than cash (net debt) at Mar 2026.
Questions
What is Gujarat Themis Biosyn Limited's P/E ratio?
Investors pay ₹79.1 for every ₹1 of Gujarat Themis Biosyn Limited's yearly profit, higher than 86% of Healthcare companies in India.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Gujarat Themis Biosyn Limited: ₹4,600 Cr ÷ ₹288 Cr (31 Mar 2026) = 16.0.
What is Gujarat Themis Biosyn Limited's return on equity?
Gujarat Themis Biosyn Limited earned 16.9% on its shareholders' money over the last year, higher than 65% of Healthcare companies in India.
How much does Gujarat Themis Biosyn Limited owe compared with what it owns?
Gujarat Themis Biosyn Limited owes ₹0.43 for every ₹1 it owns (low), higher than 67% of Healthcare companies in India.
Does Gujarat Themis Biosyn Limited pay a dividend?
Yes. Gujarat Themis Biosyn Limited pays 0.18% of its share price as dividends a year, lower than 72% of dividend-paying Healthcare companies in India.
Is Gujarat Themis Biosyn Limited's revenue growing?
Revenue rose 10% in the year to Mar 2026, and grew 4% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.